NeuroTrax News
5 articles
growth-positive
Study Shows Hyperbaric Oxygen Therapy (HBOT) Protocols Can Improve Cognitive Function in Stroke Patients
The Sagol Center for Hyperbaric Medicine and Research announced study results indicating that its hyperbaric oxygen therapy (HBOT) protocols induce significant improvement in cognitive function of stroke patients. The study showed that the HBOT protocols supply the energy needed for brain tissue recovery, regardless of the stroke location or cause. The study evaluated the sustained impact of the centers HBOT protocols on various cognitive domains and found that 86% of stroke patients achieved clinically significant improvement in their cognitive function. The memory domain showed the most prominent improvements. The study highlights the potential for treating stroke-related cognitive deficits as brain wounds and the ability to recover injured brain tissue even years after the stroke. The Sagol Center is a leader in hyperbaric medicine research and offers advanced hyperbaric chambers for treatment.
Customers
Digital Cognitive Testing Uncovers Hidden Impairment in MS
growth-positive
NeuroTrax BrainCare Now Available Globally, Targets Brain Wellness Post-Stroke and TBI
NeuroTrax has announced the global availability of BrainCare, a cognitive assessment and report solution designed to assist clinicians in advancing brain wellness of stroke survivors and traumatic brain injury patients. The product offers structured patient assessment and reporting, providing healthcare professionals with quality of care metrics related to brain exercises. The BrainCare assessment includes a standardized set of computerized tests intended to pinpoint cognitive and psychosocial factors. The results are used to create graphical reports for both the clinician and patient, and also offers patient activity recommendations.
Customers
growth-positive
NJIT start-up company NeuroTrax named best in show
NeuroTrax Corporation, a start-up company, has developed a computer software program for early diagnosis of Alzheimer’s, Parkinson’s, and other diseases. The program, called Mindstreams®, provides real-time objective measurement of cognitive function, enabling early diagnosis and treatment for memory loss. NeuroTrax won the most coveted title at a recent New Jersey Technology Council competition. The company is based at NJIT’s business incubator program, the Enterprise Development Center. NeuroTrax is among 83 similar technology enterprises at the Center. The software program has been established in scientific publications and presented at international conferences. NeuroTrax aims to provide a faster and more reliable way for physicians to track patients progress over time.
CustomersInvestment
growth-positive
NeuroTrax Completes $1.5 Million Funding Round and Announces Hiring of John Rooney as Chief Marketing Officer
NeuroTrax has successfully completed their Series B investment round, raising over $1.5 million from the New Jersey Economic Development Authority (EDA) and private sources. The funding will be used to continue the companys growth and expand sales and marketing efforts. NeuroTrax has also hired John Rooney as their new Chief Marketing Officer to focus on the commercialization of their cognitive testing systems. The Mindstreams Cognitive Health Assessment software provides medical professionals with an objective measurement of cognitive function parameters and has been clinically proven to detect cognitive impairment associated with Alzheimers disease and other conditions. The company aims to track patient progress over time and compare results with normative data from over 1,500 individuals. The cost of Alzheimers disease and dementia in the United States is estimated to be over $148 billion annually.
InvestmentManagement Changes
